- Home
- NERV vs PHH Comparison
NERV vs PHH Comparison
Compare NERV & PHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- PHH
- Stock Information
- Founded
- NERV 2007
- PHH 2016
- Country
- NERV United States
- PHH China
- Employees
- NERV N/A
- PHH N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- PHH Package Goods/Cosmetics
- Sector
- NERV Health Care
- PHH Consumer Discretionary
- Exchange
- NERV Nasdaq
- PHH Nasdaq
- Market Cap
- NERV 14.6M
- PHH 16.2M
- IPO Year
- NERV 2014
- PHH 2024
- Fundamental
- Price
- NERV $2.83
- PHH $0.47
- Analyst Decision
- NERV Hold
- PHH
- Analyst Count
- NERV 1
- PHH 0
- Target Price
- NERV $5.00
- PHH N/A
- AVG Volume (30 Days)
- NERV 639.5K
- PHH 575.5K
- Earning Date
- NERV 11-04-2025
- PHH 08-26-2025
- Dividend Yield
- NERV N/A
- PHH N/A
- EPS Growth
- NERV N/A
- PHH N/A
- EPS
- NERV 1.48
- PHH N/A
- Revenue
- NERV N/A
- PHH $2,768,120.00
- Revenue This Year
- NERV N/A
- PHH N/A
- Revenue Next Year
- NERV N/A
- PHH N/A
- P/E Ratio
- NERV $1.47
- PHH N/A
- Revenue Growth
- NERV N/A
- PHH 42.65
- 52 Week Low
- NERV $1.15
- PHH $0.41
- 52 Week High
- NERV $3.29
- PHH $41.49
- Technical
- Relative Strength Index (RSI)
- NERV 70.41
- PHH 23.75
- Support Level
- NERV $2.06
- PHH $0.46
- Resistance Level
- NERV $2.15
- PHH $0.50
- Average True Range (ATR)
- NERV 0.11
- PHH 0.03
- MACD
- NERV 0.02
- PHH 0.15
- Stochastic Oscillator
- NERV 70.72
- PHH 20.13
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About PHH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.